Organogenesis, MiMedx among decliners as Medicare to pull skin substitute LCDs
Source: SeekingAlpha
2025-12-26 11:09:21 ET
More on Organogenesis Holdings, MiMedx Group
- Organogenesis: High-Tech Skin Substitute Company On Sale
- Organogenesis Holdings Inc. (ORGO) Q3 2025 Earnings Call Transcript
- MiMedx: Breakout Setup Into A Policy Overhaul
- Organogenesis starts rolling submission for ReNu allograft for knee arthritis
- Organogenesis outlines 2025 revenue guidance of $500M–$525M as CMS policy shift drives growth outlook
Read the full article on Seeking Alpha
For further details see:
Organogenesis drops as Medicare to pull skin substitute LCDs (update)
Celularity Inc.
NASDAQ: CELU
CELU Trading
0.49% G/L:
$1.22 Last:
8,685 Volume:
$1.21 Open:
CELU Latest News
February 10, 2026 08:30:00 am
Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses
December 26, 2025 08:30:00 am
Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations
December 18, 2025 02:10:00 pm
Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision
CELU Stock Data
$36,623,989
16,924,239
4.59%
22
N/A
Biotechnology & Life Sciences
Healthcare
US
Florham Park
